Truist analyst Richard Newitter raised the firm’s price target on Insulet (PODD) to $412 from $390 and keeps a Buy rating on the shares. The firm cites the company’s Investor Day presentation outlining its 3-year outlook for revenue and profit, and believes that Insulet is well-positioned to maintain its lead in a rapidly growing patch category that is fueling the pump market expansion with still underpenetrated Type 1 and Type 2 diabetes categories, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $380 from $370 at RBC Capital
- Insulet price target raised to $380 from $370 at BTIG
- Insulet’s Promising Growth Potential: A Buy Rating Despite Market Skepticism
- Insulet’s Ambitious Growth Targets and Strategic Initiatives Reinforce Buy Rating with Revised Price Target of $380
- Insulet’s Strategic Growth and Innovation Drive ‘Buy’ Rating with $360 Price Target